In a bold executive move, President Trump aims to slash prescription drug costs by allowing inexpensive imports and revamping Medicare negotiations.
At a Glance
- Trump signed an executive order permitting drug imports from Canada to lower costs.
- The order seeks to streamline the Medicare drug negotiation process for better pricing.
- Initiatives to expedite generic and biosimilar drug approvals are prioritized.
- An investigation on imported medicine’s impact on national security has been initiated.
Executive Order Overview
In response to escalating prescription drug costs, President Trump signed an executive order on April 15, aiming to allow states to import cheaper medications from Canada. This strives to offer lower-cost alternatives to consumers burdened by high domestic drug prices. By revising the Medicare drug negotiation process, the administration intends to ensure more competitive pricing and transparency in drug cost structures.
Watch coverage here.
To expand on existing measures, the order also fast-tracks the approval of generics and biosimilar drugs, which typically decrease market prices significantly. President Trump’s administration seeks to resolve broker conflicts and advocate for better transparency, ultimately making essential medications, such as insulin, more accessible to American consumers.
Investigation and Proposed Tariffs
Simultaneously, President Trump considers imposing tariffs on imported medications, which might result in higher prices and potential shortages of vital drugs. The administration has launched an investigation into whether foreign drug imports and pharmaceutical ingredients threaten national security, employing Section 232 authority used before for industries like automobiles and lumber.
“pharmaceutical tariffs would come in the “not too distant future.”” – Mr. Trump.
President Trump expresses concern over the fact that the U.S. heavily relies on other countries, such as China and Ireland, for drug production. Despite hopes to shift manufacturing back to America, experts argue that implementing tariffs alone may not achieve this due to the high expenses and time needed for relocation.
Improving Drug Pricing through Legislation
The executive order directs the Department of Health and Human Services to work closely with Congress in adjusting Medicare drug pricing and ensuring better deals under Medicaid programs. Revisions in the Medicare Drug Pricing Negotiation Program authorize initial lower prices for ten drugs by early 2026. Efforts include inspiring more states to apply for drug import approvals and simplifying the FDA approval process for generics that can significantly reduce costs.
“Today, President Donald J. Trump signed an Executive Order to expand on the historic efforts of his first term to lower prescription drug prices.” – President Donald J. Trump.
In conclusion, with these strategies and directives, President Trump intends to create a more transparent, competitive, and fair prescription drug market, benefiting American patients by making life-saving medications affordable and accessible.
